Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

new protein biomarkers and use such information to develop PAD, ovarian cancer or hematology diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its PAD, ovarian cancer or hematology diagnostic products; (5) uncertainty of market acceptance of its PAD, ovarian cancer or hematology diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

- Financial statements follow -

Vermillion, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands)

(Unaudited)

March 31, December 31,

2008 2007 (1)

Assets

Current assets:

Cash and cash equivalents $8,283 $7,617

Short-term investments, at fair value - 8,875

Accounts receivable 51 19

Prepaid expenses and other current assets 1,481 1,064

Total curren
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Second generation biofuels are a viable solution to ... as natural gas is very cheap, this is affecting the ... valuable as they could be in comparison to natural gas. ... made it difficult for renewable energy developers to get the ... For these reasons, certain companies have shifted their focused within ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, applauds the ... taking a strong position in opposition to current ... 27, 2014 publication.  The New York Times also ... this week exploring the issue called "High Time:  ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grangeā„¢ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 29, 2014 G-CON Manufacturing Inc., the ... today announced a new leadership appointment designed to drive ... and abroad. , Maik Jornitz, Chief Operating Officer ... President charged with leading the pioneering company through its ... this stage of development and look forward to providing ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... Consortium With Broad ... Portfolio of IV Products, ... BAX ) announced today that Novation, the University HealthSystem,Consortium,s (UHC) ... behalf of UHC valued at over $200 million over the,contract ...
... (Pink Sheets: BIEL), announced today that the ... sale by its,distributor, Endotherapeutics Party Limited. ... professionals of,Endotherapeutics will successfully launch ActiPatch in ... of experience in the,medical devices market and ...
... to Identify Pathways and ... to Metabolomic Data, REDWOOD CITY, Calif., Oct. ... solutions to help life science researchers,generate insights from ... solution within Ingenuity,Pathways Analysis to help researchers understand ...
Cached Biology Technology:Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 3Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 2
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... 1 in 100,000 people characterized by a loss of ... unknown, a new study by a team of researchers at ... and other European institutions confirms for the first time that ... July in Nature Genetics , is an important step ... sphincter in the lower esophagus opens, allowing food to enter ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Mysterious esophagus disease is autoimmune after all 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... of the potential health effects associated with accidental exposure ... , The study, "An Analysis of Uranium Dispersal and ... by Sandia scientist Al Marshall, employs analytical capabilities used ... risks associated with uranium handling. , U.S. and British ...
... Cornell University researchers have revealed a process that has ... derived from vitamin A enters a cell's nucleus, where ... basic transport mechanism opens a new door for future ... for the fight against cancer and other diseases. , ...
... HIV is so difficult to contain and treat is its ... to that evolution is vital. , Host cells produce two ... ability to replicate. But HIV produces a protein, called Vif, ... full of variation, both in sequence and in function, according ...
Cached Biology News:Sandia completes depleted uranium study 2Study shows how retinoic acid enters a cell's nucleus 2Study shows how retinoic acid enters a cell's nucleus 3
Request Info...
Prepared in distilled water....
... white. The extinction coefficient , E(1%) at ... phosphate-buffered saline, pH 7.4, containing ... 50% glycerol. Avidin (from egg white) is conjugated ... molecular sieving and is completely ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
Biology Products: